These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 17354223)

  • 1. Decreased intraperitoneal disease recurrence in epithelial ovarian cancer patients receiving intraperitoneal consolidation treatment with yttrium-90-labeled murine HMFG1 without improvement in overall survival.
    Oei AL; Verheijen RH; Seiden MV; Benigno BB; Lopes A; Soper JT; Epenetos AA; Massuger LF
    Int J Cancer; 2007 Jun; 120(12):2710-4. PubMed ID: 17354223
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase III trial of intraperitoneal therapy with yttrium-90-labeled HMFG1 murine monoclonal antibody in patients with epithelial ovarian cancer after a surgically defined complete remission.
    Verheijen RH; Massuger LF; Benigno BB; Epenetos AA; Lopes A; Soper JT; Markowska J; Vyzula R; Jobling T; Stamp G; Spiegel G; Thurston D; Falke T; Lambert J; Seiden MV
    J Clin Oncol; 2006 Feb; 24(4):571-8. PubMed ID: 16446329
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patterns of recurrence in advanced epithelial ovarian, fallopian tube and peritoneal cancers treated with intraperitoneal chemotherapy.
    Esselen KM; Rodriguez N; Growdon W; Krasner C; Horowitz NS; Campos S
    Gynecol Oncol; 2012 Oct; 127(1):51-4. PubMed ID: 22659193
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Induction of IgG antibodies to MUC1 and survival in patients with epithelial ovarian cancer.
    Oei AL; Moreno M; Verheijen RH; Sweep FC; Thomas CM; Massuger LF; von Mensdorff-Pouilly S
    Int J Cancer; 2008 Oct; 123(8):1848-53. PubMed ID: 18661524
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Phase I study of combined modality (90)Yttrium-CC49 intraperitoneal radioimmunotherapy for ovarian cancer.
    Alvarez RD; Huh WK; Khazaeli MB; Meredith RF; Partridge EE; Kilgore LC; Grizzle WE; Shen S; Austin JM; Barnes MN; Carey D; Schlom J; LoBuglio AF
    Clin Cancer Res; 2002 Sep; 8(9):2806-11. PubMed ID: 12231520
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Progression-free and overall survival of a modified outpatient regimen of primary intravenous/intraperitoneal paclitaxel and intraperitoneal cisplatin in ovarian, fallopian tube, and primary peritoneal cancer.
    Barlin JN; Dao F; Bou Zgheib N; Ferguson SE; Sabbatini PJ; Hensley ML; Bell-McGuinn KM; Konner J; Tew WP; Aghajanian C; Chi DS
    Gynecol Oncol; 2012 Jun; 125(3):621-4. PubMed ID: 22446622
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Extraperitoneal leakage as a possible explanation for failure of one-time intraperitoneal treatment in ovarian cancer.
    Oei AL; Massuger LF; Oyen WJ
    Cancer Biother Radiopharm; 2007 Aug; 22(4):508-14. PubMed ID: 17803445
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of peritoneal carcinomatosis from ovarian cancer by surgical cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC).
    Robella M; Vaira M; Marsanic P; Mellano A; Borsano A; Cinquegrana A; Sottile A; De Simone M
    Minerva Chir; 2014 Feb; 69(1):27-35. PubMed ID: 24675244
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intraperitoneal mitoxantrone as consolidation treatment for patients with ovarian carcinoma in pathologic complete remission.
    Dufour P; Bergerat JP; Barats JC; Giron C; Duclos B; Dellenbach P; Ritter J; Renaud R; Audhuy B; Oberling F
    Cancer; 1994 Apr; 73(7):1865-9. PubMed ID: 8137212
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intraperitoneal radioactive phosphorus (32P) versus observation after negative second-look laparotomy for stage III ovarian carcinoma: a randomized trial of the Gynecologic Oncology Group.
    Varia MA; Stehman FB; Bundy BN; Benda JA; Clarke-Pearson DL; Alvarez RD; Long HJ;
    J Clin Oncol; 2003 Aug; 21(15):2849-55. PubMed ID: 12885800
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CA125 level as a predictor of progression-free survival and overall survival in ovarian cancer patients with surgically defined disease status prior to the initiation of intraperitoneal consolidation therapy.
    Juretzka MM; Barakat RR; Chi DS; Iasonos A; Dupont J; Abu-Rustum NR; Poynor EA; Aghajanian C; Spriggs D; Hensley ML; Sabbatini P
    Gynecol Oncol; 2007 Jan; 104(1):176-80. PubMed ID: 16996584
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of prognostic factors after positive second-look surgery in epithelial ovarian carcinoma.
    McCreath WA; Eisenhauer EL; Abu-Rustum NR; Venkatraman ES; Caceres A; Bier R; Huh J; Cho J; Barakat RR; Chi DS
    Gynecol Oncol; 2006 Jul; 102(1):8-14. PubMed ID: 16427689
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intraperitoneal versus intravenous cisplatin in combination with intravenous cyclophosphamide and epidoxorubicin in optimally cytoreduced advanced epithelial ovarian cancer: a randomized trial of the Gruppo Oncologico Nord-Ovest.
    Gadducci A; Carnino F; Chiara S; Brunetti I; Tanganelli L; Romanini A; Bruzzone M; Conte PF
    Gynecol Oncol; 2000 Feb; 76(2):157-62. PubMed ID: 10637064
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CA125 decline in ovarian cancer patients treated with intravenous versus intraperitoneal platinum-based chemotherapy.
    Richardson DL; Seamon LG; Carlson MJ; O'Malley DM; Fowler JM; Copeland LJ; Cohn DE
    Gynecol Oncol; 2008 Nov; 111(2):233-6. PubMed ID: 18768214
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Utilization of intraperitoneal chemotherapy for optimally cytoreduced advanced stage epithelial ovarian cancer: A 10-year single institution experience with a racially diverse urban population.
    Miller EM; Tymon-Rosario J; Xie X; Xue X; Gressel GM; Miller DT; Kuo DY; Nevadunsky NS
    Gynecol Oncol; 2017 Oct; 147(1):36-40. PubMed ID: 28751119
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Radioimmunotherapy after chemotherapy compared to chemotherapy alone in the treatment of advanced ovarian cancer: a matched analysis.
    Nicholson S; Gooden CS; Hird V; Maraveyas A; Mason P; Lambert HE; Meares CF; Epenetos AA
    Oncol Rep; 1998; 5(1):223-6. PubMed ID: 9458326
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intraperitoneal cisplatin and intravenous paclitaxel in the treatment of epithelial ovarian cancer patients with a positive second look.
    Makhija S; Sabbatini P; Aghajanian C; Venkatraman E; Spriggs DR; Barakat R
    Gynecol Oncol; 2000 Oct; 79(1):28-32. PubMed ID: 11006026
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alternative intraperitoneal chemotherapy regimens for optimally debulked ovarian cancer.
    Gray HJ; Shah CA; Swensen RE; Tamimi HK; Goff BA
    Gynecol Oncol; 2010 Mar; 116(3):340-4. PubMed ID: 19922987
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transient human anti-mouse antibodies (HAMA) interference in CA 125 measurements during monitoring of ovarian cancer patients treated with murine monoclonal antibody.
    Oei AL; Sweep FC; Massuger LF; Olthaar AJ; Thomas CM
    Gynecol Oncol; 2008 May; 109(2):199-202. PubMed ID: 18304620
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I study of 90Y-labeled B72.3 intraperitoneal administration in patients with ovarian cancer: effect of dose and EDTA coadministration on pharmacokinetics and toxicity.
    Rosenblum MG; Verschraegen CF; Murray JL; Kudelka AP; Gano J; Cheung L; Kavanagh JJ
    Clin Cancer Res; 1999 May; 5(5):953-61. PubMed ID: 10353726
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.